CITATION REPORT List of articles citing



DOI: 10.1056/nejmc053442 New England Journal of Medicine, 2006, 354, 1091-3; author reply 1091-3.

Source: https://exaly.com/paper-pdf/40977594/citation-report.pdf

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
39	Pharmacologic treatment for pulmonary arterial hypertension. <i>Current Opinion in Cardiology</i> , 2006 , 21, 561-8	2.1	9
38	[Diagnosis and treatment of pulmonary hypertension]. <i>Pneumologie</i> , 2006 , 60, 428-40; quiz 441-2	0.5	2
37	Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2007 , 30, 922-7	13.6	127
36	Sildenafil for pulmonary hypertension: dose-dependent improvement in exercise performance. <i>Pulmonary Pharmacology and Therapeutics</i> , 2008 , 21, 516-21	3.5	7
35	ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians,	16.7	829
34	Phosphodiesterase inhibitors and the eye. Clinical and Experimental Ophthalmology, 2009, 37, 514-23	2.4	34
33	Novel approaches to the pharmacotherapy of pulmonary arterial hypertension. <i>Drug Discovery Today</i> , 2009 , 14, 284-90	8.8	15
32	ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. Journal of the	15.1	1257
31	American College of Cardiology 2009, 53, 1573-619 Pulmonary arterial hypertension in systemic sclerosis. Autoimmunity Reviews, 2010, 9, 761-70	13.6	21
30	The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. <i>Vascular Health and Risk Management</i> , 2010 , 6, 273-80	4.4	21
29	Pulmonary hypertension in dogs: diagnosis and therapy. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2010 , 40, 623-41	2.4	92
28	Pulmonary hypertension and right ventricular dysfunction: physiology and perioperative management. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2011 , 25, 687-704	2.1	49
27	Pulmonary arterial hypertension: An overview. British Journal of Cardiac Nursing, 2011, 6, 268-277	0.2	1
26	Impact of first-line sildenafil monotreatment for pulmonary arterial hypertension. <i>Circulation Journal</i> , 2012 , 76, 1245-52	2.9	12
25	Pulmonary hypertension-"state of the art" management in 2012. Indian Heart Journal, 2012, 64, 60-73	1.6	2
24	Current pathophysiological concepts and management of pulmonary hypertension. <i>International Journal of Cardiology</i> , 2012 , 155, 350-61	3.2	43
23	Sildenafil alleviates bronchopulmonary dysplasia in neonatal rats by activating the hypoxia-inducible factor signaling pathway. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2013 , 48, 105-13	5.7	51

(2008-2013)

22	Signal transduction in the development of pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2013 , 3, 278-93	2.7	61
21	The first Keystone Symposia Conference on pulmonary vascular isease and right ventricular dysfunction: Current concepts and future therapies. <i>Pulmonary Circulation</i> , 2013 , 3, 275-7	2.7	2
20	Cardiac manifestations in systemic sclerosis. World Journal of Cardiology, 2014, 6, 993-1005	2.1	84
19	Bilateral posterior ischemic optic neuropathy associated with the use of Sildenafil for pulmonary hypertension. <i>Canadian Journal of Ophthalmology</i> , 2016 , 51, e96-9	1.4	6
18	Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design. <i>Respiratory Medicine</i> , 2018 , 138, 13-20	4.6	22
17	Exploring the binding mechanisms of PDE5 with chromeno[2,3-]pyrrol-9(2)-one by theoretical approaches <i>RSC Advances</i> , 2018 , 8, 30481-30490	3.7	2
16	Cross-cultural adaptation of the Cambridge Pulmonary Hypertension Outcome Review for use in patients with pulmonary hypertension in Colombia. <i>Jornal Brasileiro De Pneumologia</i> , 2019 , 45, e20180)3 3 2 ¹	2
15	Effect of a phosphodiesterase-5A (PDE5A) gene polymorphism on response to sildenafil therapy in canine pulmonary hypertension. <i>Scientific Reports</i> , 2019 , 9, 6899	4.9	6
14	Systemic sclerosis. 2019 , 291-329		
13	Type 5 phosphodiesterase (PDE5) and the vascular tree: From embryogenesis to aging and disease. <i>Mechanisms of Ageing and Development</i> , 2020 , 190, 111311	5.6	4
12	Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra. <i>British Journal of Pharmacology</i> , 2021 , 178, 172-186	8.6	7
11	Systemic Sclerosis. 2013 , 955-969		1
10	Selective serotonin reuptake inhibitor use is associated with right ventricular structure and function: the MESA-right ventricle study. <i>PLoS ONE</i> , 2012 , 7, e30480	3.7	9
9	Sildenafil in the treatment of pulmonary hypertension. <i>Vascular Health and Risk Management</i> , 2006 , 2, 411-22	4.4	88
8	Selective serotonin reuptake inhibitors and cardiovascular events: A systematic review. <i>Journal of Research in Medical Sciences</i> , 2016 , 21, 66	1.6	13
7	The nitric oxide and cyclic guanosine monophosphate pathway. 2011 , 343-352		
6	Chronic Administration of Sildenafil Citrate (Viagra) on the Frontal Cortex of Adult Male Rats: An Ultrastructural Study. <i>Forensic Medicine and Anatomy Research</i> , 2020 , 08, 38-44	0.2	1
5	PDE5 Inhibitors and the cGMP Pathway in Pulmonary Arterial Hypertension. 2008, 305-319		

Case report: Bilateral central serous chorioretinopathy-like abnormalities in a man with pulmonary arterial hypertension. 9,

3	New progress in diagnosis and treatment of pulmonary arterial hypertension. 2022, 17,	0
2	Pathogenic Mechanisms of Pulmonary Arterial Hypertension. 2022, 2, 787-802	O
1	Egln1Tie2Cre Mice Exhibit Similar Therapeutic Responses to Sildenafil, Ambrisentan, and Treprostinil as Pulmonary Arterial Hypertension (PAH) Patients, Supporting Egln1Tie2Cre Mice as a Useful PAH Model. 2023 , 24, 2391	0